TAU BIO-LOGIC announces the humanization of the monoclonal antibody Picomolar Affinity against TauC3 protein for the treatment of Alzheimer's and progressive supranuclear palsy

NEW YORK, LONDON, April 8 / PRNewswire / – TAU BIO-LOGIC CORP. announced today that it has successfully humanized a monoclonal antibody (TBL-100) directed against the truncated C-terminal tau (tauC3) in collaboration with the British group LifeArc. TAU BIO-LOGIC is developing TBL-100 for the treatment of Alzheimer's disease and progressive supranuclear palsy. The affinity of the humanized antibody to tauC3 is 13 pM (about 100 times greater than most of the therapeutic antibodies marketed to its targets) and a specificity that is 1,000-fold greater than for whole tau (FLT). The high affinity and specificity of the antibody is expected to result in improved efficacy and safety compared to other tau antibodies currently under development. TauC3 exists at a lower frequency than FLT or N-terminal truncated Tau, but exerts disproportionately large pathological effects. This is because tauC3 has the highest tendency to aggregate between all forms of tau and is also capable of recruiting normal forms of tau and forming nucleated pathological tau forms. In the case of Alzheimer's disease, tauC3 is formed early in the disease process and the level correlates with cognitive decline. TauC3 causes intracellular neurotoxicity and is also considered the most important booster of tau proliferation. A study by Professor Bradley Hyman of Harvard Medical School showed the potential of TBL-100 to block the spread of tau in AD brain (Nicholls et al., 2017; PLoS ONE 12 (5): e0177914). In progressive supranuclear palsy, the production and activity of tauC3 have been associated with a single polynuclear polymorphism (SNP) under rs1768208, a significant risk factor for the disease. Thus, TBL-100 could also be beneficial for the treatment of this disease.

The humanization of TBL-100 was performed by LifeArc under a risk sharing agreement with TAU BIO-LOGIC under conditions that would guarantee LifeArc a small royalty on future drug sales. "We are pleased to have contributed to the development of TBL-100," says Dr. Justin Bryans, head of LifeArc Center for Therapeutic Research. "The collaboration has resulted in a leading candidate for further development and several good back-up molecules that offer a combination of superior biophysical properties and thermostability, high affinity binding and high expression properties."

"Successful humanization marks an important milestone in the development of TBL-100, which we believe offers several advantages over other anti-tau and low molecular weight tau treatments under development in both safety and security. to improve effectiveness, "said Daniel G. Chain, PhD, president and CEO of TAU BIO-LOGIC. "We want to rapidly develop this promising therapeutic treatment modifying the disease for patients with Alzheimer's disease and progressive supranuclear palsy, as these diseases currently lack effective therapies."

Information on TAU BIO-LOGIC CORPORATION

TAU BIO-LOGIC is a private biopharmaceutical company focused on the development of innovative high precision immunotherapies for the treatment of Alzheimer's disease, supranuclear palsy and associated neurodegenerative diseases. The main product of the Company is TBL-100, a monoclonal antibody that binds and inhibits the activity of truncated terminal C tau (tauC3). The affinity of the humanized antibody is 13 pM (about 100 times greater than most of the therapeutic antibodies marketed for their targets) and a specificity that is 1000 times greater than that of whole tau (FLT). The high affinity and specificity of the antibody is expected to result in improved efficacy and safety compared to other tau antibodies currently under development.

About LifeArc

LifeArc is a 25-year medical research charity that helps scientists and organizations translate their research into treatments and diagnoses for patients. LifeArc helps scientific research to make a greater impact on the patient. The charity brings together a network of partners to combat certain diseases and directly funds academic research and early-stage research. So far, LifeArc's work has helped develop four approved drugs (Keytruda®, Actemra®, Tysabri® and Entyvio®) and a diagnostic test for carbapenem resistance.

Information on Alzheimer's disease

Alzheimer's disease is the leading cause of dementia and represents a huge and growing global challenge for public health, being a deadly neurodegenerative disease with no cure or substantially effective treatment. The disease now affects more than 5 million Americans, 7 million Europeans and a total of about 44 million people worldwide, according to the latest Alzheimer's Association report. So far, no disease modifying treatment has not been approved in the early or late stages of the disease.

Information on progressive supranuclear palsy

It is a rare and fatal neurodegenerative disease that affects about 20,000 people in the United States. It causes progressive deficits in the sense of balance and gait, compromised eye movements, abnormal muscle tone, speech disorders and problems associated with swallowing and eating. In addition, those affected often experience personality changes and cognitive impairments. Symptoms usually begin after age 60, but may occur earlier. The exact cause is unknown, and the disease is often erroneously misdiagnosed as Parkinson's disease. So far, no disease modifying treatment has not been approved in the early or late stages of the disease.

OTS: Writing TAU BIO-LOGIC: http://www.presseportal.de/nr/134369 newsroom via RSS: http://www.presseportal.de/rss/pm_134369.rss2

Press contact:

Daniel G. Chain, PhD, President and CEO of TAU-BIOLOGIC; [email protected] Paul Brennan, vice president of business development at TAU-BIOLOGIC; [email protected] Logo – https://mma.prnewswire.com/media/873067/TBL_Logo.jpg